# Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom

Source: https://onco.cc/trials/nct07239596/  
OnCo record `nct07239596` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SHR-8068 in renal cell carcinoma, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.

## Summary

Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom is a phase 1/2 interventional study registered as NCT07239596 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 92 participants planned, started 2026-01-06 and due to reach its primary completion in 2030-12. Interventions recorded: SHR-8068；Adebrelimab ；Bevacizumab, SHR-8068 ; SHR-4610. Conditions listed: Advanced Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07239596
- Phase: 1/2
- Setting: An Open, Multicenter Phase Ib/II Clinical Study of SHR-8068 in Combination Anti-tumor Drugs for the Treatment of Advanced Renal Cell Carcinoma
- Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Enrolled: 92

## Sources

- ClinicalTrials.gov NCT07239596: https://clinicaltrials.gov/study/NCT07239596

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [SHR-8068](https://onco.cc/drugs/shr-8068/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07239596.json